1512MO Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV)

Changhui Li ,K Wang,Yang Zheng ,Xiaohua Wang ,Kai Yin ,Zhiqiang Wang ,Peng Zhao ,Jiahong Dong ,Andrew Zhang ,Yuan Tian ,Li Yang ,Zheng Zhang ,Huijiao Chen ,Fei Yuan ,Qingjun Zhao ,Zhen Shi ,Xu Shu ,Lian Chen ,Chao Zhang ,Zheng Zhu

doi:10.1016/j.annonc.2023.09.1425

1512MO Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV)

Changhui Li , K Wang + Show 18 more

https://doi.org/10.1016/j.annonc.2023.09.1425

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2023
Citations: 3

#Resectable Gastric Adenocarcinoma #Advanced Gastroesophageal Junction + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1512MO Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV)

Full Text